Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
2.

Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.

Bouvard B, Chatelais J, Soulié P, Hoppé E, Saulnier P, Capitain O, Mege M, Mesgouez-Nebout N, Jadaud E, Abadie-Lacourtoisie S, Campone M, Legrand E.

Eur J Cancer. 2018 Sep;101:87-94. doi: 10.1016/j.ejca.2018.06.028. Epub 2018 Jul 20.

PMID:
30036740
3.

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M.

Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Review.

4.

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.

Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, Denis F, Zinger M, Juhel-Voog L, Lafond C, Maillart P, Capitain O, Delva R, Soulié P, Abadie-Lacourtoisie S, Guérin-Meyer V, Morin-Meschin ME, Commer JM, Gangler A, d'Aillières B, Zannetti A, Bourbouloux E, Berton-Rigault D, Lebouvier-Sadot S, Kaassis M, Baudon J, Lam YH, Bizieux A, Marcq M, Edeline J, Le Du F, Lefeuvre C, Deguiral P, Delecroix V, Blot E, Egreteau J, Goudier MJ, Lamy R, Ferec M, Artignan X, Corbinais S, Morel H, Hardy-Bessard AC, Alleaume C, Naudeix E, Cojocarasu O, Metges JP, Riché C, Gamelin E, Déniel-Lagadec D, Marhuenda F, Ingrand P, Douillard JY.

Ann Oncol. 2017 Jul 1;28(7):1612-1617. doi: 10.1093/annonc/mdx172.

PMID:
28472235
5.

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M.

Eur J Cancer. 2016 Jul;62:28-35. doi: 10.1016/j.ejca.2016.04.003. Epub 2016 May 15.

PMID:
27192659
6.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A.

Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.

PMID:
27052658
7.

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T.

Ann Oncol. 2015 Jan;26(1):120-5. doi: 10.1093/annonc/mdu497. Epub 2014 Oct 31.

PMID:
25361980
8.

Fracture incidence after 3 years of aromatase inhibitor therapy.

Bouvard B, Soulié P, Hoppé E, Georgin-Mege M, Royer M, Mesgouez-Nebout N, Lassalle C, Cellier P, Jadaud E, Abadie-Lacourtoisie S, Tuchais C, Vinchon-Petit S, Audran M, Chappard D, Legrand E.

Ann Oncol. 2014 Apr;25(4):843-7. doi: 10.1093/annonc/mdu008. Epub 2014 Mar 7.

PMID:
24608193
9.

Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study.

Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, Capitain O.

J Neurooncol. 2014 Apr;117(2):253-9. doi: 10.1007/s11060-014-1378-5. Epub 2014 Jan 31.

PMID:
24481998
10.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.

PMID:
23764181
11.

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.

Falandry C, Brain E, Bonnefoy M, Mefti F, Jovenin N, Rigal O, Guillem O, El Kouri C, Uwer L, Abadie-Lacourtoisie S, Cretin J, Jacquin JP, Paraiso D, Freyer G.

Eur J Cancer. 2013 Sep;49(13):2806-14. doi: 10.1016/j.ejca.2013.04.027. Epub 2013 Jun 1.

PMID:
23735702
12.

[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].

Latteux G, Lebdai S, Hoarau N, Abadie-Lacourtoisie S, Delva R, Chautard D, Azzouzi AR, Bigot P.

Prog Urol. 2013 Mar;23(3):184-94. doi: 10.1016/j.purol.2012.09.014. Epub 2012 Oct 25. French.

PMID:
23446283
13.

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.

J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.

PMID:
22565002
14.

High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.

Bouvard B, Hoppé E, Soulié P, Georgin-Mege M, Jadaud E, Abadie-Lacourtoisie S, Petit Le Manac'h A, Laffitte A, Levasseur R, Audran M, Chappard D, Legrand E.

Ann Oncol. 2012 May;23(5):1151-6. doi: 10.1093/annonc/mdr356. Epub 2011 Sep 7.

PMID:
21903604
15.

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

Pivot X, Lortholary A, Abadie-Lacourtoisie S, Mefti-Lacheraf F, Pujade-Lauraine E, Lefeuvre C, Letessier S, Morvan P, Dür C, Frimat L.

Breast. 2011 Dec;20(6):510-4. doi: 10.1016/j.breast.2011.05.006. Epub 2011 Jul 2.

PMID:
21727006
16.

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).

Rousseau F, Retornaz F, Joly F, Esterni B, Abadie-Lacourtoisie S, Fargeot P, Luporsi E, Servent V, Laguerre B, Brain E, Geneve J; Programme d’Action Concertée GERIatrie onCOlogie (PAC GERICO).

Crit Rev Oncol Hematol. 2010 Oct;76(1):71-8. doi: 10.1016/j.critrevonc.2009.12.003. Epub 2010 Mar 30.

PMID:
20356760
17.

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.

Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E.

Pharmacogenomics J. 2008 Aug;8(4):256-67. Epub 2007 Aug 14.

PMID:
17700593
18.

Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.

Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.

Am J Clin Oncol. 2006 Jun;29(3):267-75.

PMID:
16755180
19.

[Influence of the delay between conservative surgery and radiation therapy on local relapse in node-positive breast tumor].

Benchalal M, Boisselier P, de Lafontan B, Berton-Rigaud D, Belkacemi Y, Romestaing P, Peignaux K, Courdi A, Monnier A, Montcuquet P, Goudier MJ, Marchal C, Chollet P, Abadie-Lacourtoisie S, Datchary J, Veyret C, Kerbrat P.

Bull Cancer. 2006 Mar 1;93(3):303-13. French.

20.

[Cytolytic hepatitis and esomeprazole during chemotherapy].

Capitain O, Lortholary A, Abadie-Lacourtoisie S.

Presse Med. 2005 Oct 8;34(17):1235-6. French.

PMID:
16230965
21.

Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.

Benchalal M, Le Prisé E, de Lafontan B, Berton-Rigaud D, Belkacemi Y, Romestaing P, Peignaux K, Courdi A, Monnier A, Montcuquet P, Goudier MJ, Marchal C, Chollet P, Abadie-Lacourtoisie S, Datchary J, Veyret C, Kerbrat P.

Cancer. 2005 Jul 15;104(2):240-50.

22.

[Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide].

Paillocher N, Lortholary A, Abadie-Lacourtoisie S, Morand C, Verriele V, Catala L, Descamps P.

J Gynecol Obstet Biol Reprod (Paris). 2005 Feb;34(1 Pt 1):41-6. Review. French.

23.

[Isolated increase in alkaline phosphatase following ingestion of sertraline].

Morand C, Paillocher N, Lortholary A, Petit S, Abadie-Lacourtoisie S.

Presse Med. 2004 Sep 11;33(15):1010. French. No abstract available.

PMID:
15523249
24.

[Cancers of unknown origin: 311 cases].

Lortholary A, Abadie-Lacourtoisie S, Guérin O, Mege M, Rauglaudre GD, Gamelin E.

Bull Cancer. 2001 Jun;88(6):619-27. French.

Supplemental Content

Loading ...
Support Center